Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
16.59
+0.16 (1.00%)
Aug 12, 2025, 4:00 PM - Market closed

Paramount Global Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202016 - 2020
Period Ending
Aug '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2020
19,02525,00611,70310,1298,83510,576
Upgrade
Market Cap Growth
4.45%113.68%15.54%14.65%-16.46%-1.18%
Upgrade
Enterprise Value
34,38941,28130,33430,27531,94535,841
Upgrade
Last Close Price
16.4222.0410.449.128.019.65
Upgrade
PE Ratio
----21.19-
Upgrade
Forward PE
6.308.354.213.633.023.76
Upgrade
PS Ratio
1.121.510.740.680.560.64
Upgrade
PB Ratio
2.764.371.441.180.790.96
Upgrade
P/FCF Ratio
21.3633.3913.909.7237.4416.58
Upgrade
P/OCF Ratio
13.6820.058.566.3711.078.70
Upgrade
PEG Ratio
0.906.690.401.630.680.54
Upgrade
EV/Sales Ratio
2.072.501.912.032.012.15
Upgrade
EV/EBITDA Ratio
7.609.327.007.637.257.77
Upgrade
EV/EBIT Ratio
9.8312.249.5411.3710.3811.73
Upgrade
EV/FCF Ratio
38.6455.1236.0329.06135.3656.18
Upgrade
Debt / Equity Ratio
2.573.182.502.522.102.40
Upgrade
Debt / EBITDA Ratio
3.763.984.535.265.195.57
Upgrade
Debt / FCF Ratio
19.7124.2824.0820.8099.9741.59
Upgrade
Asset Turnover
0.410.400.360.330.320.31
Upgrade
Inventory Turnover
2.262.412.092.082.022.02
Upgrade
Quick Ratio
0.480.500.540.570.610.51
Upgrade
Current Ratio
1.060.981.021.051.140.99
Upgrade
Return on Equity (ROE)
-2.42%-28.30%-7.36%-25.19%4.09%-31.38%
Upgrade
Return on Assets (ROA)
5.37%5.09%4.54%3.63%3.91%3.53%
Upgrade
Return on Capital (ROIC)
8.77%8.06%6.78%5.11%5.31%4.77%
Upgrade
Return on Capital Employed (ROCE)
12.40%12.70%10.20%8.20%8.40%8.20%
Upgrade
Earnings Yield
-0.83%-6.55%-4.78%-24.15%4.72%-37.73%
Upgrade
FCF Yield
4.68%3.00%7.20%10.29%2.67%6.03%
Upgrade
Buyback Yield / Dilution
-1.25%-1.07%-0.81%-0.27%-1.10%-0.37%
Upgrade
Total Shareholder Return
-1.25%-1.07%-0.81%-0.27%-1.10%-0.37%
Upgrade
Updated Jul 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q